Local consolidative therapy does not improve survival after dual immunotherapy in metastatic NSCLC
· Medical Xpressby International Association for the Study of Lung Cancer
edited by Sadie Harley, reviewed by Andrew Zinin
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
proofread
The GIST Add as preferred source
Adding local consolidative therapy (LCT) after induction treatment with nivolumab plus ipilimumab did not improve overall survival or progression-free survival in patients with metastatic non-small cell lung cancer (NSCLC), including those with oligometastatic disease, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).
Local consolidative therapy has improved outcomes in selected patients with oligometastatic NSCLC treated with chemotherapy, but its role in patients receiving immune checkpoint inhibitors has remained uncertain. The Phase III LONESTAR trial tested whether reducing residual tumor burden with radiation or surgery after dual immunotherapy could improve systemic disease control.
"In this randomized trial, adding local consolidative therapy after induction dual checkpoint blockade was feasible, but it did not improve overall survival or progression-free survival in the overall population or among patients with oligometastatic disease," said Mehmet Altan, M.D., of MD Anderson Cancer Center, Houston, Texas.
LONESTAR was an open-label, single-center, randomized trial in immunotherapy-naive patients with metastatic NSCLC. After 12 weeks of induction with nivolumab plus ipilimumab, patients without progression or dose-limiting toxicity were randomized to continue nivolumab/ipilimumab alone or receive LCT followed by nivolumab/ipilimumab. LCT consisted of radiation to at least one disease site, with surgery performed when feasible.
At the June 15, 2026, data cutoff, 166 patients were randomized: 83 to nivolumab/ipilimumab alone and 83 to LCT followed by nivolumab/ipilimumab. Seventy-seven patients had oligometastatic disease at randomization, and 16 patients in the LCT arm underwent surgery. Seventy-one patients in the LCT arm received radiation to at least one disease site.
In the overall randomized population, median overall survival was 52.8 months with nivolumab/ipilimumab alone compared with 43.2 months with LCT plus nivolumab/ipilimumab (HR 1.14; 95% CI, 0.75–1.74; P = .54). Median progression-free survival was 24.3 months versus 31.3 months, respectively (HR 0.79; 95% CI, 0.54–1.15; P = .22).
Among patients with oligometastatic disease, median overall survival was 75.8 months with nivolumab/ipilimumab alone versus 42 months with LCT plus nivolumab/ipilimumab. Median progression-free survival was 44.0 months versus 35.7 months, respectively.
LCT did not increase the overall incidence of grade 3 or higher adverse events, although pneumonitis was numerically more frequent in the LCT arm, occurring in 9.5% of patients compared with 4.9% with nivolumab/ipilimumab alone. Investigators also observed markedly lower absolute lymphocyte counts when systemic therapy was restarted in the LCT arm.
The investigators concluded that adding LCT after induction dual checkpoint blockade was feasible but did not improve overall or progression-free survival in an unselected metastatic NSCLC population, including patients with oligometastatic disease.
Key medical concepts
Clinical categories
OncologyPulmonary medicine Provided by International Association for the Study of Lung Cancer Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Local consolidative therapy does not improve survival after dual immunotherapy in metastatic NSCLC (2026, September 12) retrieved 12 September 2026 from https://medicalxpress.com/news/2026-09-local-therapy-survival-dual-immunotherapy.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.